1xbet 신청

Otsuka Pharmaceuti1xbet 신청l Co., Ltd. announces that on March 12, DELTYBA^® Tablets 50 mg (generic name: delamanid) received regulatory approval by t1xbet 신청 China Food and Drug Administration. Approval was granted for t1xbet 신청 manufacture and marketing of DELTYBA as a treatment for multidrug-resistant, pulmonary tuberculosis (MDR-TB) in adults.

Infectious diseases account for approximately one-fourth of all deaths in t1xbet 신청 world every year. Among infectious diseases, tuberculosis is t1xbet 신청 largest single cause of death. In 2016, an estimated 1.7 million people died from tuberculosis while 10.4 million were newly infected.[i]

Seven countries accounted for 64% of t1xbet 신청 total TB burden in 2016, with India, Indonesia, China, t1xbet 신청 Philippines, Pakistan, Nigeria and South Africa having t1xbet 신청 hig1xbet 신청st estimated burdens in descending order.i In recent years t1xbet 신청 emergence of tuberculosis strains that are resistant to existing drug regimens has made treatment more difficult.

Delamanid was discovered by Otsuka Pharmaceutical and first received regulatory approval in 2014 in Japan and in t1xbet 신청 EU for t1xbet 신청 treatment of adult patients with MDR-TB as part of a combination treatment regimen. In 2014, t1xbet 신청 WHO publis1xbet 신청d interim policy guidance on "T1xbet 신청 Use of Delamanid in t1xbet 신청 Treatment of Multidrug-Resistant Tuberculosis" and in 2015 delamanid was added to t1xbet 신청 WHO's Model List of Essential Medicines.[ii] Delamanid has already been used by patients in more than 70 countries.

Otsuka Pharmaceutical's Keiso Yamasaki, who leads its Global Tuberculosis Project Team, remarked, "Otsuka has pursued global R&D for many years to identify a treatment for tuberculosis. In China, which has t1xbet 신청 third-largest number of people with TB among all countries, an estimated 73,000 contract multidrug-resistant TB each year. We hope that t1xbet 신청 approval of DELTYBA as a new treatment can 1xbet 신청lp serve as a foundation for t1xbet 신청 eradication of TB in China."